CytRx Corporation (CYTR) to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
11/18/2009 9:00:35 AM
More...
|
CytRx Corporation (CYTR) Reports 2009 Third Quarter Financial Results
11/9/2009 9:51:38 AM
More...
|
CytRx Corporation (CYTR) Announces Publication of Paper Stating that Chaperone Amplification Represents a ‘Significant Strategy’ in Anti-aging Pharmaceutical Design
10/28/2009 8:59:46 AM
More...
|
CytRx Corporation (CYTR) Fortifies Executive Suite with Addition of Chief Medical Officer
10/13/2009 8:56:22 AM
More...
|
CytRx Corporation (CYTR) and Cephalon, Inc. (CEPH) Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
9/14/2009 9:34:13 AM
More...
|
CytRx Corporation (CYTR) Secures Key European Patent for Arimoclomol
9/10/2009 9:41:31 AM
More...
|
CytRx Corporation (CYTR) to Present at the Sachs Associates Annual Biotech in Europe Investor Forum
9/9/2009 9:19:21 AM
More...
|
CytRx Corporation (CYTR) Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial for ALS
9/8/2009 9:06:12 AM
More...
|
CytRx Corporation (CYTR)'s Arimoclomol Demonstrates Statistically Significant Cellular Evidence of Both Neuroprotection and Neuroregeneration in Animal Stroke Study
8/24/2009 9:13:00 AM
More...
|
CytRx Corporation (CYTR)'s Drug Candidate INNO-206 Produces Statistically Significant Tumor Shrinkage in Animal Model of Small Cell Lung Cancer
8/12/2009 8:30:41 AM
More...
|
|